A Phase Ib Study Evaluating Safety, Pharmacokinetic and Pharmacodynamic Profiles of a Single Course of TL011 Infusions in Subjects With Severe, Active Rheumatoid Arthritis
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Teva Pharmaceutical Industries
- 14 May 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
- 14 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2012 Actual patient number (48) added as reported by ClinicalTrials.gov.